Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 1 Baseline characteristics of the body mass index < 25 kg/m² and body mass index ≥ 25 kg/m² groups, n (%)

Variables	BMI < 25 kg/m2 (n = 51)	BMI ≥ 25 kg/m2 (n = 75)	χ2	P value
HBV DNA (IU/mL)			0.31	0.579
HBV > 2000	25 (49.02)	33 (44.00)
HBV ≤ 2000	26 (50.98)	42 (56.00)
HBe			2.05	0.152
Negative	32 (62.75)	56 (74.67)
Positive	19 (37.25)	19 (25.33)
Child-Pugh class			0.52	0.472
A	28 (54.90)	46 (61.33)
B	23 (45.10)	29 (38.67)
PVTT			3.12	0.077
No	26 (50.98)	50 (66.67)
Yes	25 (49.02)	25 (33.33)
BCLC stage			0.30	0.586
B	24 (47.06)	39 (52.00)
C	27 (52.94)	36 (48.00)
Metastasis			0.00	0.979
No	28 (54.90)	41 (54.67)
Yes	23 (45.10)	34 (45.33)
AFP (ng/mL)			3.01	0.083
> 1210	27 (52.94)	28 (37.33)
≤ 1210	24 (47.06)	47 (62.67)
Sex			0.97	0.323
Female	16 (31.37)	30 (40.00)
Male	35 (68.63)	45 (60.00)
Age (years)			1.00	0.316
< 60	26 (50.98)	45 (60.00)
≥ 60	25 (49.02)	30 (40.00)
ECOG			3.49	0.062
0-1	27 (52.94)	52 (69.33)
2	24 (47.06)	23 (30.67)
ALT (U/L)			1.14	0.286
> 40	26 (50.98)	31 (41.33)
≤ 40	25 (49.02)	44 (58.67)
Total bilirubin (μmol/L)			1.29	0.256
> 34	35 (68.63)	44 (58.67)
≤ 34	16 (31.37)	31 (41.33)
Diabetes			0.83	0.361
No	41 (80.39)	55 (73.33)
Yes	10 (19.61)	20 (26.67)
Hypertensive			0.11	0.736
No	15 (29.41)	20 (26.67)
Yes	36 (70.59)	55 (73.33)
Cirrhosis			0.18	0.675
No	28 (54.90)	44 (58.67)
Yes	23 (45.10)	31 (41.33)
Smoking			1.33	0.248
No	31 (60.78)	53 (70.67)
Yes	20 (39.22)	22 (29.33)
Alcohol			0.47	0.491
No	35 (68.63)	47 (62.67)
Yes	16 (31.37)	28 (37.33)
Interventional			0.84	0.358
No	25 (49.02)	43 (57.33)
Yes	26 (50.98)	32 (42.67)

BMI: Body mass index; HBV: Hepatitis B virus; PVTT: Portal vein tumor thrombosis; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; ECOG: Eastern Cooperative Oncology Group; ALT: Alanine aminotransferase.